Illumination of immune checkpoint LAG3 ‘black box’ could yield new cancer and autoimmune therapies
A new study pinpoints how an immune checkpoint protein called LAG3 modulates T cell activity, providing important insights for development of LAG3-blocking therapies for cancer and autoimmune disorders.
Materials provided by University of Pittsburgh. Note: Content may be edited for style and length.
Source link aaaaa